Table 1 Patients characteristics of training set and validation set
Variate | Training set | Validation set | P- value |
|---|---|---|---|
Tumour size | |||
⩽5 cm | 107 (54.3%) | 39 (45.3%) | 0.1961 |
>5 cm | 90 (45.7%) | 47 (54.7%) | |
Histological type | |||
Differentiated | 66 (33.5%) | 28 (32.6%) | 0.8767 |
Undifferentiated | 131 (66.5%) | 58 (67.4%) | |
T stage | |||
t1 | 91 (46.2%) | 19 (22.1%) | 0.0003 |
t2 | 57 (28.9%) | 28 (32.6%) | |
t3 | 40 (20.3%) | 35 (40.7%) | |
t4 | 9 (4.6%) | 4 (4.7%) | |
Lymph node metastasis | |||
Negative | 106 (53.8%) | 23 (26.7%) | <0.0001 |
Positive | 91 (46.2%) | 63 (73.3%) | |
Peritoneal wash cytology | |||
Class I | 100 (50.8%) | 78 (90.7%) | <0.0001 |
Class II | 74 (37.6%) | 3 (3.5%) | |
Class III | 5 (2.5%) | 4 (4.7%) | |
Class IV | 1 (0.5%) | 0 (0.0%) | |
Class V | 17 (8.6%) | 1 (1.2%) | |
CEA mRNA status in peritoneal wash | |||
Negative | 142 (72.1%) | 66 (76.7%) | 0.4657 |
Positive | 55 (27.9%) | 20 (23.3%) | |
Operative type | |||
Distal gastrectomy | 133 (67.5%) | 45 (52.3%) | 0.0635 |
Proximal gastrectomy | 12 (6.1%) | 6 (6.9%) | |
Total gastrectomy | 51 (25.9%) | 33 (38.4%) | |
Pancreaticoduodenectomy | 1 (0.5%) | 2 (2.3%) | |
Adjuvant chemotherapy | |||
Yes | 41 (20.8%) | 11 (12.8%) | 0.1334 |
No | 156 (79.2%) | 75 (87.2%) |
